EXT2

Across TCGA pan-cancer cohorts, EXT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXT2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EXT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXT2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

UCEC, PDAC, and LSCC are the cancer types where EXT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.754	0.961	<.001	30	view →
PDAC	OS	Median	All	0.442	0.637	.003	25	view →
LSCC	DFS	Quartile	All	0.194	0.927	<.001	12	view →
HNSC	DFS	Tertile	III,IV	0.855	0.642	.015	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXT2–UCEC (DFS)

Open the UCEC breakdown →